Classifieds Business Directory Jobs Real Estate Autos Legal Notices ePubs Subscribe Archives
Today is October 7, 2015
home news sports feature opinionfyi society obits multimedia

Front Page » October 28, 2008 » Opinion » Guest editorial: FDA needs guts, not PR
Published 2,535 days ago

Guest editorial: FDA needs guts, not PR

Print PageEmail PageShareGet Reprints

The Food and Drug Administration's (FDA's) management has it wrong again: The agency's troubles aren't due to bad public relations. At least they weren't until recently.

This has been yet another tormented year for the FDA. February brought congressional hearings into the agency's lax regulation of fatal drugs. March brought a congressional report scorching the FDA for its woefully inadequate inspection of foreign products entering the United States, shockingly illustrated by that month's Chinese ingredient-tainted Heparin scandal that involved at least 81 American deaths. The summer months brought the FDA's long struggle to contain a salmonella outbreak that it attributed to tomatoes, but was caused by peppers.

What was the FDA's response to this string of spotlighted failures? To hire a marketing firm to remake the agency's public image.

Comically, the FDA botched that task, too. Investigative reports show the agency circumvented the mandated competitive bidding process in order to steer the PR contract to a Washington, D.C.-based consulting firm.

After the failures of Vioxx, the respiratory drug Ketek, bacteria laden spinach and a roster of other safety lapses, it's obvious why the agency is seeking a reputation boost. But this won't come about through Madison Avenue spin jobs.

This PR debacle is a microcosm of the inherent problem at FDA that must be addressed: Officials are more concerned with limiting bad press and helping corporate friends than with safeguarding public health.

There is a clear path to fixing these fatal flaws, but it won't happen overnight. A new generation of FDA leadership must provide sustained support for decisions based on sound science rather than politics or the marketing imperatives of drug companies.

It used to be this way. Dr. Frances Kelsey is the signature example of a diligent FDA scientist who safeguarded the public health. In the early 1960s, Dr. Kelsey held fast to scientific integrity in the face of industry pressure, and was able to block Thalidomide, which caused horrific birth defects, from reaching the U.S. market. As a result, she was lauded publicly and received a major award from President John F. Kennedy in a White House ceremony. She continued to work for the FDA for another 40 years and, upon her retirement in 2002, the agency named an award in her honor.

Tragically, the FDA treats today's Dr. Kelseys as pariahs or enemies. When Dr. David Graham sought to warn the public that the painkiller Vioxx was related to tens of thousands of deaths, he needed congressional intervention just to save his job and keep his findings from being suppressed by FDA brass.

FDA veterinarian Dr. Victoria Hampshire's investigation, concluding that a heartworm drug was related to hundreds of dog fatalities, resulted in her removal without explanation from reviewing the drug. The FDA placed her under criminal investigation, and it took a subsequent senate investigation to vindicate her of any wrongdoing.

Today's FDA works at cross-purposes, tethered to its industry patrons when it should be singularly focused on the public good. The FDA's Office of New Drugs, tasked with determining whether new drugs are safe, is largely funded by industry user fees. How are these fees determined? By industry and agency officials sitting down behind closed doors and negotiating terms of the drug approval process (without any consumer or patient representatives). Once the FDA approves a drug and it is on the market, the agency's Office of Surveillance and Epidemiology (OSE) is to monitor its safety. But OSE has no independent authority to take action against unsafe drugs, only the "power" to make a recommendation to the very body that approved the drug in the first place.

To restore trust in the agency, the FDA must be restructured so that its drug approval function is not tainted by industry conflicts, and its oversight function is not subordinated to its drug approval branch.

Drs. Graham and Hampshire are just two of many FDA employees who should be praised for coming forward. Their diligence in the face of industry pressure and subterfuge are the sort of everyday heroism that safeguards public health. Encouraging rather than subverting this type of work will make for credible, honest and effective PR for the FDA and restore the public's trust.

Corrupt PR contracts will not.

Jonathan Cantu is public health and safety associate for the Government Accountability Project, the nation's leading whistleblower protection and advocacy organization.

Print PageEmail PageShareGet Reprints

Top of Page

October 28, 2008
Recent Opinion
Quick Links
Subscribe via RSS
Related Articles  
Related Stories

Best viewed with Firefox
Get Firefox

© Sun Advocate, 2000-2013. All rights reserved. All material found on this website, unless otherwise specified, is copyright and may not be reproduced without the explicit written permission from the publisher of the Sun Advocate.
Legal Notices & Terms of Use    Privacy Policy    Advertising Info    FAQ    Contact Us
  RSS Feeds    News on Your Site    Staff Information    Submitting Content    About Us